All Products

Featured Products

Newest Products

Research Areas

AEZS-112

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200115

CAS#: 1214741-69-1

Description: AEZS-112, also known as ZEN012, is an orally active small mol. anti-cancer drug which inhibits the polymn. of tubulin at low micromolar concns. AEZS 112 dose-dependently increased non-vital hypodiploid cells and the cytotoxic effect was least pronounced in G2 phase of the cell cycle, indicating cell death during mitosis, as detd. by FACS anal. AEZS 112 showed anti-tumor activity in human ovarian and endometrial cancer cell lines at low micromolar concns., which could not be abrogated by caspase inhibition and is therefore a good candidate for in vivo studies in these tumors.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity
Pricing updated 2020-08-13. Prices are subject to change without notice.

AEZS-112, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200115
Name: AEZS-112
CAS#: 1214741-69-1
Chemical Formula: C25H23N3O2
Exact Mass: 397.17903
Molecular Weight: 397.46902
Elemental Analysis: C, 75.54; H, 5.83; N, 10.57; O, 8.05


Synonym: ZEN012; ZEN 012; ZEN-012; AEZS112; AEZS 112; AEZS-112.

IUPAC/Chemical Name: 9-Acridinyl[4-(3-methoxyphenyl)-1-piperazinyl]methanone

InChi Key: YTECZQLINBWBIQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H23N3O2/c1-30-19-8-6-7-18(17-19)27-13-15-28(16-14-27)25(29)24-20-9-2-4-11-22(20)26-23-12-5-3-10-21(23)24/h2-12,17H,13-16H2,1H3

SMILES Code: O=C(C1=C(C=CC=C2)C2=NC3=CC=CC=C31)N4CCN(C5=CC=CC(OC)=C5)CC4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

AEZS-112 is currently developed by Æterna Zentaris Inc. AEZS-112 is the first anticancer drug in development involving two mechanisms of action, tubulin and topoisomerase II inhibition. AEZS-112 expresses different modes of action such as, pro-apoptotic and anti-angiogenic properties.
 
Mode of action studies revealed that the compound AEZS-112 inhibits the polymerization of ß-tubulin in low micromolar concentrations. Competition studies suggest that AEZS-112 interacts with the same binding site on microtubules as colchicine. AEZS-112 destroys the mitotic spindles of the cancer cells, arrests the cancer cells in G2/M phase at low concentrations, mediates DNA fragmentation via inhibition of topoisomerase II and induces apoptosis via various mechanisms. See  Æterna Zentaris Inc's website.
 
 


References

1: Kwok CW, Treeck O, Buchholz S, Seitz S, Ortmann O, Engel JB. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol. 2014 Oct 9. [Epub ahead of print] PubMed PMID: 25293576.

2: Engel JB, Schönhals T, Weidler C, Häusler S, Krockenberger M, Rieger L, Dietl J, Wischhusen J, Honig A. Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep. 2009 Aug;22(2):361-7. PubMed PMID: 19578778.